# Development of Read-outs in Healthy, Hepatitis B Virus Naive Adults Vaccinated With the Hepatitis B Surface Antigen (HBsAg) in Combination With a GlaxoSmithKline (GSK) Biologicals' Adjuvant System

> **NCT01777295** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 81 (actual)

## Conditions studied

- Hepatitis B

## Interventions

- **BIOLOGICAL:** Adjuvanted Hepatitis B surface antigen (HBsAg) candidate vaccine GSK2231392A.
- **BIOLOGICAL:** EngerixTM-B
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT01777295
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-02-25
- **Primary completion:** 2016-05-17
- **Final completion:** 2016-09-13
- **Target enrollment:** 81 (ACTUAL)
- **Last updated:** 2019-01-04

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01777295

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01777295, "Development of Read-outs in Healthy, Hepatitis B Virus Naive Adults Vaccinated With the Hepatitis B Surface Antigen (HBsAg) in Combination With a GlaxoSmithKline (GSK) Biologicals' Adjuvant System". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT01777295. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*